Gram-negative bacteria are defined by their envelope, and the envelope is the reason most antibacterial programs stall. A compound can have excellent affinity for an essential Gram-negative target and still be completely inactive on the organism, because it never gets to the target in a useful concentration.
The envelope, layer by layer
- Inner membrane. A conventional phospholipid bilayer.
- Periplasm and peptidoglycan. A thin cell wall layer sitting in an aqueous compartment that also contains degradative enzymes, including beta-lactamases.
- Outer membrane. Asymmetric: phospholipid on the inside, lipopolysaccharide on the outside. The LPS leaflet is densely packed, strongly anionic and cross linked by divalent cations. It is a poor solvent for hydrophobic molecules.
The Gram stain that gives the group its name is a direct read of this architecture: the thin peptidoglycan layer does not retain crystal violet, so the cells take the safranin counterstain instead.
How anything gets in
There are two realistic routes across the outer membrane.
- Porin channels. Water filled protein pores that admit small, hydrophilic molecules. Practical limits are low: roughly under 600 daltons, polar, and not strongly hydrophobic. Beta-lactams and fluoroquinolones use this route.
- Self promoted uptake. Polycationic agents such as the polymyxins displace the divalent cations holding LPS together and permeabilise their own way in. Effective, and the reason colistin still matters.
Work on compound accumulation in E. coli has produced practical guidance, often summarised as the eNTRy rules: an ionisable nitrogen, low three dimensional complexity and limited flexibility tend to favour accumulation. That guidance points in almost the opposite direction to conventional lead optimisation, which is covered in the post on lead optimization for antibacterials.
Efflux, the second barrier
Getting in is not enough, because RND family efflux pumps span both membranes and export compounds straight back out. The pumps are constitutively expressed and can be strongly upregulated.
| Organism | Principal RND pump | Practical effect |
|---|---|---|
| E. coli | AcrAB-TolC | Broad substrate range, raises MICs across several classes |
| P. aeruginosa | MexAB-OprM and relatives | Major contributor to intrinsic resistance |
| A. baumannii | AdeABC | Combines with low outer membrane permeability |
| K. pneumoniae | AcrAB | Often stacked with porin loss and a carbapenemase |
Uptake and efflux act together. A compound that enters slowly and is exported quickly reaches a periplasmic concentration far below what the target needs, and the resulting MIC looks like a potency problem when it is actually a transport problem. Distinguishing those two is exactly what a mechanism level read-out is for.
Which organisms matter most
The Gram-negative members of the ESKAPE group carry most of the clinical burden: Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species, alongside Escherichia coli. When these acquire a carbapenemase the remaining options narrow sharply, which is the subject of the carbapenem resistance page.
What this means for a screening panel
Three practical consequences:
- A Gram-positive result tells you little about Gram-negative activity. Screen both or you are guessing.
- A flat inactive row across all Gram-negatives usually means uptake, not affinity. The fix is chemistry on polarity and charge, not on the pharmacophore.
- Activity on E. coli but not on P. aeruginosa is the classic efflux signature, and it points at a specific pump rather than at a dead scaffold.
The screen below is preselected for the Gram-negative panel. Paste a structure and read which of those three patterns your compound produces.